Efficacy and safety of octreotide in laparoscopic hepatectomy surgery: effect on blood loss, need for vasoactive drugs, transfusion requirement. - HEPA-OCT

niversity Clinic Of Navarra0 个研究点目标入组 62 人开始时间: 2023年3月15日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Patients diagnosed with hepatic lesions who are going to undergo laparoscopic hepatectomy., The patient must be between 18 and 80 years old., The patient, or his/her representative, has given his/her consent to participate in the study., The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial., The patient must not be allergic to the drug.

•History of hypersensitivity to the drug to be administered, Children under 18 years of age., Urgent intervention., Intervention performed in an open manner (not laparoscopic)., Patient's refusal to participate in the study., Contraindication to receive octreotide., Women of childbearing age (those women who are in the period between menarche and menopause). Having to present a negative pregnancy test to take part in the study., Pregnant or lactating women given the absence of studies of this drug in this patient profile.

发起方

niversity Clinic Of Navarra